Go BACK

OUH STUDIES

Studies currently being run within Oxford University Hospitals NHS Foundation Trust.

Showing 581 - 590 of 763 studies

Cardiovascular

A Phase 2A, Double-blind, Randomized, Placebo-controlled, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986435/MYK-224 in Participants with Heart Failure with Heart Failure with Preserved Ejection Fraction (HFpEF) (CV029-1001 (AURORA))

Musculoskeletal

A 2-Part, Randomized, Double-Blind, Placebo-Controlled Study in Participants with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping with an Initial Multiple Ascending Dose Part A to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ENTR-601-45, Followed by Part B to Evaluate the Safety and Efficacy of ENTR-601-45 (ELEVATE-45)

Predicting the Pain Outcome of Surgery for Endometriosis (PrePOSE)

Safety and Clinical Performance of the Drug Eluting Resorbable Coronary MAGnesium Scaffold System (Freesolve®) in the Treatment of Subjects with de Novo Lesions in Native Coronary Arteries. (BIOMAG II)

Cancer and neoplasms

An Open-Label, Phase 2 study to evaluate safety, tolerability and preliminary activity of the CTPS1 inhibitor STP938 in adult subjects with high risk essential thrombocythaemia who are resistant to or intolerant of hydroxycarbamide therapy (STP938-301(VECTRA))

Eye

A Long-term Follow-Up Study to Evaluate the Safety and Efficacy of RGX-314 Following Subretinal Administration in Participants with Neovascular Age-related Macular Degeneration And Fellow Eye Treatment Substudy

Unmasking concealed arrhythmia syndromes (RASE BRUGADA GEL)

Cutaneous Responses to Diphenylcyclopropenone to evaluate Immunomodulatory Therapeutics (CUREDIT)

A prospective pilot cohort study to investigate the accuracy and utility of wearables in preoperative assessment in addition to cardiopulmonary exercise testing in predicting outcomes for patients who have undergone oesophagogastric cancer surgery.

Musculoskeletal

A 2-Part, Randomized, Double-Blind, Placebo-Controlled Study in Participants with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping with an Initial Multiple Ascending Dose Part A to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ENTR-601-44, Followed by Part B to Evaluate the Safety and Efficacy of ENTR-601-44 (ELEVATE-44) (ENTR-601-44-201 (ELEVATE-44))